Keytruda showed superior long-term survival benefits over Yervoy in unresectable stage 3 or 4 melanoma, with improved OS, PFS, and MSS rates. The 10-year follow-up data confirmed Keytruda's role as a ...
Moderna and Merck's combination therapy for skin cancer helped reduce risk of cancer spreading to another part of the body ...
The combination of intismeran autogene and Keytruda reduced recurrence or death risk by 49% in high-risk melanoma patients over five years. The study involved 157 patients with stage 3/4 melanoma who ...
LOS ANGELES -- Patients with metastatic melanoma have faced grim prospects: the American cancer society says the five-year survival rate is only 15 percent. That started changing when the FDA approved ...
A breakthrough personalized mRNA cancer vaccine that trains the immune system to target patients' unique tumor mutations is showing promising results. Five-year trial data show the risk of recurrence ...
A late-stage trial evaluating Regeneron’s fianlimab, a skin cancer drug, fails to meet its primary endpoint.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results